Compare · ABT vs ARVN
ABT vs ARVN
Side-by-side comparison of Abbott Laboratories (ABT) and Arvinas Inc. (ARVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ARVN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.13B, about 249.7x ARVN ($633.2M).
- Over the past year, ABT is down 30.7% and ARVN is up 37.2% - ARVN leads by 67.9 points.
- ABT has been more active in the news (27 items in the past 4 weeks vs 2 for ARVN).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- Arvinas Inc.
- Price
- $90.64-0.80%
- $9.89+0.61%
- Market cap
- $158.13B
- $633.2M
- 1M return
- -11.68%
- -6.79%
- 1Y return
- -30.71%
- +37.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 27
- 2
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Arvinas Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Latest ABT
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
- Director Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)
- Director Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)
- Director Roman Michael F was granted 2,286 units of Common shares without par value, increasing direct ownership by 27% to 10,764 units (SEC Form 4)
- Director O'Grady Michael was granted 2,286 units of Common shares without par value, increasing direct ownership by 43% to 7,603 units (SEC Form 4)
- Director Mckinstry Nancy was granted 2,286 units of Common shares without par value, increasing direct ownership by 6% to 41,010 units (SEC Form 4)
Latest ARVN
- SEC Form DEFA14A filed by Arvinas Inc.
- SEC Form DEF 14A filed by Arvinas Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.
- SEC Form 4 filed by Berkowitz Noah
- Arvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days
- SEC Form 144 filed by Arvinas Inc.
- Amendment: President and CEO Teel Randy was granted 147,179 shares, increasing direct ownership by 98% to 296,875 units (SEC Form 4)
- Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
- Director Morrison Briggs bought $268,070 worth of shares (20,000 units at $13.40), increasing direct ownership by 26% to 96,021 units (SEC Form 4)